Sitagliptin Hydrochloride

盐酸西格列汀

Report date: 2024/03/07 10:08:50

Base Information

Drug NameSitagliptin Hydrochloride
Drug Alias Name西格列汀盐酸盐
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Polycystic Ovary Syndrome
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySpain
Original Approved Date2019/03/06
Country/TerritoryCanadaEgyptSpain +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLaboratorios Alter Sa
China Registration ClassN/A

Develop Information

Active CompaniesAccord Healthcare SluBeni Suef UniversityLaboratorios Alter Sa
Inactive CompaniesGalenicum Health
Active IndicationsDiabetes Mellitus, Type 2Polycystic Ovary Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeA10BH01
Related LinksWikipediaKEGG